DDX5和DDX17在卵巢癌组织中的表达及对人卵巢癌细胞系SKOV3增殖和耐药的影响

doi:10.16352/j.issn.1001-6325.2023.08.1247

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (8): 1247-1253.doi: 10.16352/j.issn.1001-6325.2023.08.1247

DDX5和DDX17在卵巢癌组织中的表达及对人卵巢癌细胞系SKOV3增殖和耐药的影响

黄洁, 李润博, 郭建新, 韩健^*

陆军军医大学陆军特色医学中心妇产科,重庆 400042

收稿日期:2022-10-24 修回日期:2022-12-31 出版日期:2023-08-05 发布日期:2023-07-26
通讯作者: ^*hj_obgyn@tmmu.edu.cn
基金资助:
陆军军医大学优秀人才库项目(B-3271)

Expression of DDX5 and DDX17 in ovarian cancer tissues and their effects on proliferation and drug resistance of human ovarian cancer cell line SKOV3

HUANG Jie, LI Runbo, GUO Jianxin, HAN Jian^*

Department of Obstetrics and Gynecology, Army Medical Center of PLA, Army Medical University, Chongqing 400042, China

Received:2022-10-24 Revised:2022-12-31 Online:2023-08-05 Published:2023-07-26
Contact: ^*hj_obgyn@tmmu.edu.cn

摘要/Abstract

摘要： 目的分析DDX5和DDX17在卵巢癌中的表达水平及与患者生存期的关系,并研究其对人卵巢癌细胞系SKOV3增殖及耐药的影响。方法选取40例卵巢癌和27例正常卵巢上皮标本,采用RT-qPCR检测DDX5和DDX17的表达;应用TCGA数据库分析卵巢癌中DDX5和DDX17与患者生存预后的关系;用慢病毒介导的DDX5-shRNA和DDX17-shRNA下调SKOV3细胞中DDX5和DDX17的表达,Western blot验证敲降效果,CCK8法检测细胞增殖能力及对紫杉醇和卡铂的药物敏感性。结果与正常卵巢上皮相比,卵巢癌组织中 DDX5的表达升高,而DDX17的表达明显降低(P＜0.05);高表达DDX5的卵巢癌患者具有较短的无进展生存期和总生存期,而高表达DDX17的卵巢癌患者则有更长的无进展生存期和总生存期;DDX5表达下调抑制SKOV3细胞增殖,而DDX17表达下调后促进增殖; DDX5表达下调后SKOV3细胞对紫杉醇和卡铂的药物敏感性明显增加,而DDX17表达下调后SKOV3细胞对紫杉醇和卡铂的药物敏感性变化不明显。结论 DDX5和DDX17能够调节卵巢癌细胞系的增殖与耐药,可能是卵巢癌发生发展中的重要调节因子。

关键词: 卵巢癌, DDX5, DDX17, 增殖, 耐药

Abstract: Objective To analyze the expression of DDX5 and DDX17 in ovarian cancer and their relationship with patient survival, and to study the effects of DDX5 and DDX17 on proliferation and drug resistance of ovarian cancer cell line SKOV3. Methods The expression of DDX5 and DDX17 was detected by RT-qPCR in tissue samples from 40 cases of ovarian carcinoma and 27 controls. TCGA database was used to analyze the relationship between DDX15/DDX17 and survival prognosis of ovarian cancer patients. The expression of DDX5 and DDX17 in SKOV3 was down-regulated by lentivirus-mediated DDX5-shRNA and DDX17-shRNA. Western blot was used to verify the knockdown effect, and CCK8 was used to detect cell proliferation and resistance to paclitaxel and carboplatin. Results Compared with normal ovarian epithelium, the expression of DDX5 in samples from ovarian carcinoma was increased, while that of DDX17 was decreased significantly(P＜0.05); Ovarian cancer patients with high DDX5 expression had shorter progression-free survival and overall survival time, while those with high DDX17 expression had longer progression-free survival and overall survival time. Down-regulated DDX5 expression inhibited the SKOV3 cells proliferation, while down-regulated DDX17 expression promoted SKOV3 cells proliferation. The drug sensitivity of SKOV3 cells to paclitaxel and carboplatin was significantly increased after the down-regulation of DDX5 expression, while the drug sensitivity of SKOV3 cells to paclitaxel and carboplatin was not significantly changed after the down-regulation of DDX17 expression. Conclusions DDX5 and DDX17 regulate proliferation and drug resistance of ovarian cancer cells, and are potential regulatory factors functioning in ovarian cancer.

Key words: ovarian cancer, DDX5, DDX17, proliferation, drug resistance

中图分类号:

黄洁, 李润博, 郭建新, 韩健. DDX5和DDX17在卵巢癌组织中的表达及对人卵巢癌细胞系SKOV3增殖和耐药的影响[J]. 基础医学与临床, 2023, 43(8): 1247-1253.

HUANG Jie, LI Runbo, GUO Jianxin, HAN Jian. Expression of DDX5 and DDX17 in ovarian cancer tissues and their effects on proliferation and drug resistance of human ovarian cancer cell line SKOV3[J]. Basic & Clinical Medicine, 2023, 43(8): 1247-1253.

参考文献 16

[1]	Wang Z, Guo E, Yang B, et al. Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer[J]. Gynecol Oncol, 2021, 163:358-363.
[2]	Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 1:1-9.
[3]	Ali MAM. DEAD-box RNA helicases: The driving forces behind RNA metabolism at the crossroad of viral replication and antiviral innate immunity[J]. Virus Res, 2021, 296:198352. doi: 10.1016/j.virusres.2021.198352.
[4]	Nyamao RM, Wu J, Yu L, et al. Roles of DDX5 in the tumorigenesis, proliferation, differentiation, metastasis and pathway regulation of human malignancies[J]. Biochim Biophys Acta Rev Cancer, 2019, 1871:85-98.
[5]	Xue Y, Jia X, Li C, et al. DDX17 promotes hepatocellular carcinoma progression via inhibiting Klf4 transcriptional activity[J]. Cell Death Dis, 2019, 10:814-825.
[6]	Wu KJ. The role of miRNA biogenesis and DDX17 in tumorigenesis and cancer stemness[J]. Biomed J, 2020, 43:107-114.
[7]	姚莎莎,尚文雯,徐睿,等. 沉默PDK1基因抑制卵巢癌细胞系SKOV3的增殖及侵袭[J]. 基础医学与临床, 2019, 39: 1381-1387.
[8]	Wills B, Fan Q, Alexander C, et al. Confusion following treatment of ovarian cancer[J]. Am J Med, 2019, 132: e610-e611.
[9]	Luo Q, Que T, Luo H, et al. Upregulation of DEAD box helicase 5 and 17 are correlated with the progression and poor prognosis in gliomas[J]. Pathol Res Pract, 2020, 216:152828. doi: 10.1016/j.prp.2020.152828.
[10]	郭菲菲,康岚. Ddx5和Ddx17在肿瘤中的表达调控及意义[J]. 中国科技论文在线精品论文, 2018, 11:862-870.
[11]	Zhou HZ, Li F, Cheng ST, et al. DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis[J]. Hepatology, 2022, 75:847-865.
[12]	Wortham NC, Ahamed E, Nicol SM, et al. The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer[J]. Oncogene, 2009, 28:4053-4064.
[13]	Giraud G, Terrone S, Bourgeois CF. Functions of DEAD box RNA helicases DDX5 and DDX17 in chromatin organization and transcriptional regulation[J]. BMB Rep, 2018, 51:613-622.
[14]	Cui Y, Hunt A, Li Z, et al. Lead DEAD/H box helicase biomarkers with the therapeutic potential identified by integrated bioinformatic approaches in lung cancer[J]. Comput Struct Biotechnol J, 2020, 19:261-278.
[15]	Zhang L, Li X. DEAD-box RNA helicases in cell cycle control and clinical therapy[J]. Cells, 2021, 10:1540-1560.
[16]	Xu K, Sun S, Yan M, et al. DDX5 and DDX17-multifaceted proteins in the regulation of tumorigenesis and tumor progression[J]. Front Oncol, 2022, 12:943032.doi: 10.3389/fonc.2022.943032.

DDX5和DDX17在卵巢癌组织中的表达及对人卵巢癌细胞系SKOV3增殖和耐药的影响

Expression of DDX5 and DDX17 in ovarian cancer tissues and their effects on proliferation and drug resistance of human ovarian cancer cell line SKOV3

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 16

相关文章 15

编辑推荐

Metrics

本文评价

[1]	肖艳红, 姜明东, 林叶远, 冉灿, 梁博. 灯盏花乙素抑制人前列腺癌细胞系PC-3的增殖和迁移[J]. 基础医学与临床, 2024, 44(9): 1229-1235.
[2]	姚安军, 陈凌子, 金惠仙. 二十二碳六烯酸抑制人结肠癌细胞系HT-29增殖[J]. 基础医学与临床, 2024, 44(8): 1107-1112.
[3]	郑红, 陈晓霞, 韩李周, 陈苗, 皇甫娟. 降低lncRNA-RMRP表达抑制人肺癌细胞系A549的增殖和侵袭[J]. 基础医学与临床, 2024, 44(7): 974-978.
[4]	曹清文, 祁琳, 禹博, 田晨晨, 袁海宁, 王越. 红景天苷促进人血管内皮细胞系EA.hy926增殖与迁移[J]. 基础医学与临床, 2024, 44(7): 925-930.
[5]	张鹏举, 李杰, 张梦迪, 孙少科, 许寅喆. KAT8通过增强METTL3表达促进结直肠癌细胞系增殖[J]. 基础医学与临床, 2024, 44(7): 931-939.
[6]	高寅洁, 童安莉. 醛固酮产生腺瘤中细胞死亡和增殖机制[J]. 基础医学与临床, 2024, 44(6): 758-762.
[7]	宋丽丽, 管玉洁, 马平, 李宁. 急性髓系白血病患儿柔红霉素耐药与PD-L1蛋白表达相关[J]. 基础医学与临床, 2024, 44(6): 833-839.
[8]	王婷婷, 萧宁, 林佃新, 董海涛. 大蒜素抑制口腔癌细胞系CAL27的增殖[J]. 基础医学与临床, 2024, 44(5): 673-676.
[9]	贾安娜, 郭金鑫, 张璇, 战世佳, 于永波, 郭永丽, 常艳. TMEFF1对神经母细胞瘤细胞系增殖的调控[J]. 基础医学与临床, 2024, 44(5): 637-644.
[10]	梁香存, 魏小雨, 梁健, 王庆, 耿广. 安罗替尼通过调控miR-16-5p/PD-1轴抑制人非小细胞肺癌细胞系增殖并促进凋亡[J]. 基础医学与临床, 2024, 44(4): 503-512.
[11]	陆凯, 陆建菊, 郭文利, 黄建棋, 李志华. lncRNA VIM-AS5在人乳腺癌细胞系中的表达及对乳腺癌细胞增殖和迁移的影响[J]. 基础医学与临床, 2024, 44(4): 447-453.
[12]	杨铠菲, 朱静格, 张洋洋, 赵俊果, 高雨悦, 胡焕焕, 姬国杰. 索拉菲尼诱导的细胞凋亡和自噬对HeLa细胞耐药性的影响[J]. 基础医学与临床, 2024, 44(4): 467-473.
[13]	郭泓江, 徐也婷, 张迪雅, 仇佳星, 王钰铖, 鞠瑞, 郭磊. 羧胺三唑乳清酸盐对人胰腺癌细胞系增殖及脂肪酸合成代谢的影响[J]. 基础医学与临床, 2024, 44(4): 440-446.
[14]	李娜, 李涛, 杨冬梨, 姚媛. 和厚朴酚抑制人脂肪间充质干细胞增殖[J]. 基础医学与临床, 2024, 44(4): 483-488.
[15]	王子豪, 夏小超, 李舜. 跨膜蛋白质在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 398-402.